News Quantified

INCY – incyte corporation (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Incyte (INCY) had its price target lowered by UBS Group AG from $104.00 to $94.00. They now have a "neutral" rating on the stock.

Incyte Announces Executive Leadership Appointments

Incyte (INCY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.

Incyte (INCY) had its "overweight" rating reaffirmed by Barclays PLC.

Incyte: An Undervalued Healthcare Gem [Seeking Alpha]

-5.4%

BEAT

-5.7%

BEAT

-0.7%

BEAT

-1.7%

MISS

Form 8-K INCYTE CORP For: Mar 25

Form 4 INCYTE CORP For: Mar 17 Filed by: CAGNONI PABLO J

Form 144 INCYTE CORP Filed by: CAGNONI PABLO J

Form 8-K INCYTE CORP For: Feb 27

Form 4 INCYTE CORP For: Feb 19 Filed by: CAGNONI PABLO J

Top News Gainers

4/5 Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium 7.1%

7/30 Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs 6.4%

3/13 Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. They now have a $83.00 price target on the stock. 6.4%

3/26 Incyte Names New Member to Its Board of Directors 5.9%

1/13 Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.7%

11/25 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting 5.3%

4/15 Form 4 INCYTE CORP For: Apr 13 Filed by: Pasquale Maria E 5.2%

2/18 Form 4 INCYTE CORP For: Feb 13 Filed by: Pasquale Maria E 4.0%

9/19 Form 4 INCYTE CORP For: Sep 18 Filed by: SWAIN PAULA J 4.0%

3/24 Blair likes Incyte in premarket analyst action [Seeking Alpha] 3.5%

Top News Decliners

1/2 Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease -9.4%

5/10 Form 4 INCYTE CORP For: May 09 Filed by: Iyengar Vijay K -6.1%

3/26 Form 8-K INCYTE CORP For: Mar 25 -5.6%

6/7 Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP -5.0%

9/23 Incyte to Host Investor Conference Call from ESMO 2019 -4.6%

1/28 Incyte's skin disease drug meets main goal in late-stage study [Reuters] -3.8%

3/10 Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating [Investor's Business Daily] -3.2%

9/27 Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma -3.2%

9/12 Incyte Co. (NASDAQ: INCY) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating on the stock. -3.1%

8/27 BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 -3.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day